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Dengue, a disease caused by any of the four serotypes of dengue viruses, 
is the most important arthropod-borne viral disease in the world in terms 
of both morbidity and mortality. The infection by these viruses induces a 
plethora of clinical manifestations ranging from asymptomatic infections 
to severe diseases with involvement of several organs. Severe forms of 
the disease are more frequent in secondary infections by distinct serotypes 
and, consequently, a dengue vaccine must be tetravalent. Although several 
approaches have been used on the vaccine development, no vaccine is 
available against these viruses, especially because of problems on the 
development of a tetravalent vaccine. Here, we describe briefly the vaccine 
candidates available and their ability to elicit a protective immune response. 
We also discuss the problems and possibilities of any of the vaccines in 
final development stage reaching the market for human use.
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Dengue is an acute febrile illness caused by the infec-
tion with any of dengue viruses. These arthropod-borne 
viruses belong to the genus Flavivirus from the family 
Flaviviridae, and are serologically classified into 
four distinct serotypes, dengue-1 to -4 (DENV-1 to 
DENV-4). These viruses are transmitted to humans by 
the bite of infected females of Aedes mosquitos, mainly 
by Aedes aegypti,35 and generate a lifelong protective 
immune response against homologous dengue strains 
and transient cross-protection against the other sero-
types for a few months after the primary infection.35
Dengue viruses cause an important and rapidly 
spreading arboviral disease and are widely distributed in 
tropical and subtropical regions of the world.2 Dengue is 
endemic in more than 100 countries including Southeast 
Asia, South and Central America, the Caribbean and 
South Pacific regions and, among them, more than 60 
countries have now reported dengue hemorrhagic fever 
(DHF).35 The World Health Organization (WHO) esti-
mates that 50 to 100 million dengue infections occur 
annually and that approximately 2.5 billion people live 
in endemic areas where 500,000 to 1,000,000 dengue 
infections evolve to DHF/dengue shock syndrome 
(DSS), resulting in approximately 25,000 deaths.35 
However, these numbers could be underestimated, and 
this hypothesis has been corroborated by a recent study 
by Bhatt et al,2 who used a formal modeling framework 
and suggest that approximately 390 million humans are 
infected every year, more than three times the previ-
ously reported by WHO.
A considerable portion of dengue virus infections 
result in asymptomatic infections, but also in clinical 
manifestations that include mild undifferentiated fever, 
dengue fever, and many more severe disease manifesta-
tions, the most studied one being DHF/DSS, in which 
the increased vascular permeability is the hallmark.35
Up to now, no animal model has allowed to conclude 
which are the precise mechanisms involved in the patho-
genesis of dengue virus infection. Therefore, the patho-
physiologic processes on the causation of severe dengue 
infections are not completely understood in spite of 
several studies that have addressed this issue. Several 
hypotheses that include mechanisms involving both 
viral and host factors have been proposed, such as the 
virulence of different virus strains,24 host genetics,5,27 the 
multifactorial interaction,17 the immune-mediated mech-
anisms,4,8 and the antibody-dependent enhancement.14 
The latter phenomenon, mainly observed in epidemio-
logical studies, may have an important role in the patho-
genesis of DHF/DSS and is related to an enhancement 
of the disease severity after a secondary infection. The 
non-neutralizing heterotypic antibodies from a first 
infection enhance the viral entry into Fc gamma receptor 
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(FcγR)-bearing cells, thus enhancing the viral load and 
consequently increasing the immune response.13,29
Currently, there is no specific drug for dengue treat-
ment, and mosquito control is mandatory to contain 
the disease in affected countries. In this context, a 
preventive dengue vaccine is essential to control the 
disease and has been a priority for the WHO for several 
decades. The challenges to vaccine development lay 
on the complex immunopathogenesis of the disease, 
especially the antibody-dependent enhancement of 
infection phenomenon, requiring the development of 
tetravalent vaccines. These vaccines should provide 
long-term protection against all virus serotypes, an 
essential requirement to vaccine approval by regula-
tory agencies.35 Dengue vaccine research ranges from 
traditional methods of virus inactivation to advanced 
molecular biology strategies. Here we discuss these 
strategies briefly and point the problems with each one 
and the perspectives for a licensed dengue vaccine.
Dengue vaccine candidates under development 
and on clinical trials
DNA vaccines
In recent decades, DNA vaccination has been used to 
induce cellular immune responses against various anti-
gens, using in vitro or animal models, some of them 
being evaluated on clinical trials. This technology is 
based on cloning a specific fragment or gene into a 
bacterial plasmid containing a strong promoter for 
optimal expression in mammalian cells. Several preclin-
ical DNA vaccine candidates were engineered against 
DENV but, up to this present publication, only two have 
been approved to be tested in humans.
A monovalent plasmid DNA vaccine against DENV-1 
(D1ME100) that encodes the premembrane (prM) and 
envelope (E) proteins was tested in 22 healthy adults 
by intramuscular injection. Phase 1 trial results showed 
this vaccine candidate to be safe, but only five subjects 
that received higher doses (5 mg) had detectable 
neutralizing antibody responses (about 20.0%). An 
increase in IFN-γ expression and DENV-1 serotype 
cross-reactivity immune responses to DENV-2, -3 and 
-4 were also reported.1
Another DNA vaccine candidate approved for phase I 
of clinical trial, produced by the U.S. Naval Medical 
Research Center and Vical Incorporated, is a Tetravalent 
DENV Vaccine (TVDV) that also encodes prM and 
E genes, but from all serotypes (1-4), in a backbone 
plasmid VR1012 (Vical Incorporated). Preclinical 
studies immunizing Indian rhesus monkeys with this 
tetravalent vaccine associated with Vaxfectin® adjuvant 
(Vical Incorporated) showed lower viremia in animals 
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inoculated with the TVDV + Vaxfectin® when challenged 
with live DENV-2 than control animals. The authors also 
reported a 2- to 10-fold increase in the neutralizing anti-
body response against DENV-1, -3 and -4.22
Although DNA vaccines seem to be an excellent 
approach to the development of dengue vaccines, the 
tests with these vaccine candidates are in their infancy, 
compared with other strategies.
Live attenuated and inactivated virus vaccines
Live attenuated virus vaccines have been success-
fully developed for other viruses and this strategy has 
also been used to develop a dengue vaccine candidate. 
These vaccines, made of weakened viruses, are excel-
lent immunogens because they can induce humoral and 
cellular immune responses similar to a natural infec-
tion, but viral replication is insufficient to produce 
disease. The attenuated vaccine for yellow fever virus, 
another virus from the genus Flavivirus, is one of the 
most effective available in the market.23 The produc-
tion of an attenuated vaccine against dengue virus 
was not as successful as for yellow fever virus. The 
Walter Reed Army Institute of Research (WRAIR) and 
GlaxoSmithKline (GSK) have infected primary dog 
kidney (PDK) cells with all four DENV serotypes to 
produce a tetravalent DENV vaccine expecting these 
vaccines to produce low viremia in recipients.33 The 
vaccine, which is in clinical phase II, was tested in 
flavivirus-naive Thai adults and showed to be safe and 
immunogenic. After two immunization doses, almost 
all subjects became seropositive to all DENV types.33 
This approach, tested in adults and infants (by WRAIR 
and Mahidol University, respectively), did not show the 
same seroconversion success.28,32
On the other hand, inactivated vaccines are made from 
viruses that become noninfectious by heating or form-
aldehyde inactivation. They are safer than attenuated 
virus candidates because of the inability of reversion 
to virulence and do not represent any harm to immuno-
compromised individuals. A tetravalent dengue inacti-
vated vaccine (DPIV), developed by Fiocruz (Brazil) 
in collaboration with GSK and WRAIR, is on phase I 
clinical trial, and showed to be protective and immu-
nogenic in nonhuman primates in a preclinical test.11
Recombinant protein vaccines
Recombinant subunit vaccines are widely developed 
for several pathogens because of their safety profile, but 
they do not produce the same immunological responses 
to pathogens as live attenuated vaccines since they 
contain only one or few viral proteins. The DENV enve-
lope protein is the most immunogenic and generally used 
for vaccine production.7 Hawaii Biotech/Merck devel-
oped a subunit vaccine candidate against all dengue 
serotypes containing a truncated E protein (DEN-80E) 
expressed in Drosophila S2 cells.9 Preclinical results 
showed an induction of high-titer neutralizing antibodies 
in both mice and nonhuman primates when administered 
with a specific adjuvant (ISCOMATRIXTM – CSL).9 This 
vaccine is currently in phase I clinical trial in healthy 
young Australian adults, and three doses will be admin-
istered at monthly intervals.
The chimeric dengue virus vaccines
The yellow fever/dengue virus (CYD) vaccine is the 
one in the most advanced stage on dengue vaccine 
development, being evaluated on large-scale clinical 
trials around the world and tested in more than 10,000 
children in five Southeast Asian countries and in more 
than 20,000 subjects in five countries in Latin America, 
including Brazil.20 This vaccine candidate is based on 
a yellow fever virus backbone (vaccine strain 17D) 
with the yellow fever virus prM and E genes replaced 
by DENV type-specific prM and E genes.
The results of the phase IIb clinical trial that took place 
in Thailand were released recently.26 In this study, 
4,002 healthy Thai schoolchildren aged 4 to 11 years 
were randomly assigned to receive three injections of 
dengue vaccine or control (rabies vaccine or placebo) 
at zero, six and 12 months to assess its protective effi-
cacy against virologically confirmed, symptomatic 
dengue occurring one month or longer after the third 
dose. Dengue disease occurred in 134 children during 
the study. Overall efficacy for all four serotypes was 
30.2%, but only 9.0% for DENV-2, although neutral-
izing antibodies, measured shortly after the last doses, 
had relatively high mean titers.
The most recent results, obtained in a phase III study 
carried out in the Asia-Pacific region that evaluated 
10,275 healthy children aged 2 to 14 years, were consis-
tent with the phase IIb in Thailand, and the overall effi-
cacy was 56.5%, but only 35.0% for DENV-2.6 Perhaps 
the best news of this vaccine was a decrease in cases 
of dengue hemorrhagic fever, the most severe form of 
the disease, by 88.5%. Of greater concern is the rela-
tive vaccine inefficacy in dengue virus-naive partici-
pants (35.5%), suggesting that this vaccine boosts and 
broadens preexisting immunity rather than primarily 
raising protective immunity, which might also explain 
the better efficacy in older children exposed to the virus.34 
Another issue of concern is the lower efficacy against 
DENV-2 disease, although it is hard to explain why the 
presence of specific neutralizing antibodies is unprotec-
tive against dengue. Viral interference poses a probable 
problem in live tetravalent formulations resulting in an 
unequal immune response to each of the four serotypes.15
It had already been observed in early preclinical studies 
with CYD vaccine in monkeys that the simultaneous 
administration of tetravalent formulations produces a 
hierarchy of immune responses, with DENV-4 showing 
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the best and DENV-2 the worst ones.12 Also, the concept 
that the infection with one serotype will confer lifelong 
protection to subsequent infections against serotypes 
from different regions of the world is under scrutiny. 
Most cohort studies on this concept were done in areas 
where each serotype is represented by a single circu-
lating genotype and the role of genotypic variation of a 
serotype in repeated infections is less certain.31
Sabchareon et al26 hypothesized that the poor level of 
protection of CYD vaccine could be due to a mismatch 
between the vaccine strain and the genetically divergent 
circulating DENV-2 Asian strain. Studies with mouse 
and human convalescent sera show that the neutralizing 
activity against DENV-3 from different genotypes of the 
same serotype varies in the ability to neutralize the virus 
infection in vitro.19,25,30 If true, this hypothesis has an enor-
mous impact in future dengue vaccines, because instead of 
a universal vaccine, each vaccine candidate will have to be 
designed to specific circulating strains around the world.
Lastly, the lack of DENV T-cell immunity in CYD 
vaccine is the most likely reason for the lack of 
multitypic protective immunity.15 Data from mouse 
models and recent studies in humans suggest that T-cell 
immunity contributes importantly to protection against 
infection by different serotypes of DENV. In this regard, 
the role of nonstructural proteins (NS) in eliciting 
cellular immunity is being considered in dengue vaccine 
approaches. Studies with DENV-infected patients or 
volunteers receiving candidate vaccines evidenced 
CD4+ and CD8+ T-cell epitopes throughout NS3.18 It 
is plausible that vaccines presenting yellow fever virus 
but not DENV nonstructural protein antigens, such as 
the CYD vaccine, do not mount a strong and protec-
tive anti-DENV T-cell response.15
The chimeric live attenuated DENV-2/DENV 
vaccine (DENVax)
The DENVax was constructed using the backbone of 
the cell culture attenuated DENV-2 (PDK-53 strain), in 
which the prM and E genes of DENV-2 PDK-53 were 
substituted with those of wild-type DENV-1, -3, or -4.16 
DENVax is undergoing extensive safety and tolerability 
tests on phase I and II clinical trials in Colombia, Puerto 
Rico, Singapore and Thailand. In Colombia, 96 healthy 
individuals aged 18 to 45 years were assigned to receive 
two doses of tetravalent DENVax 90 days apart. Results 
show that the vaccine was well tolerated and immuno-
genic. Thirty days after a second dose, 62.0% of patients 
seroconverted to all four dengue serotypes.21 The next 
steps will concentrate in the efficacy trials. Although 
promising results are expected, the lessons learned with 
Chimerivax vaccine draw our attention to the fact that 
protection against dengue disease should not rely solely 
in humoral immunity but also in the cellular immune 
responses. Thus, additional markers of protection such 
as T-cell activation, interferon-gamma (INF-g) and 
tumor necrosis factor-alpha (TNF-a) production should 
be used on immunogenicity assays.15
The chimeric live attenuated DENV/DENV vaccine 
(TetraVax-DV)
Another approach was used to produce a different 
tetravalent DENV vaccine (TetraVax-DV vaccine). 
Attenuation was achieved by a deletion of 30 nucleotides 
(Δ30) on 3’ untranslated region of wild-type DENV-1 and 
-4. Since this approach did not result in attenuation for 
the other two viruses, DENV-2 chimeric vaccine candi-
date was generated by replacing prM and E genes on the 
DEN4Δ30 backbone with those of the wild-type viruses 
and DENV-3 vaccine candidate by additional deletion of 
the 3’ untranslated region, respectively. These vaccine 
candidates retain wild-type structural proteins to maxi-
mize infectivity, thereby decreasing the potential for 
virus interference, and also to increase the magnitude 
and extension of the neutralizing antibody response.3,7
TetraVax has been tested for safety and immunogenicity 
in flavivirus-naive subjects in the United States. All 
vaccines were safe and immunogenic and one formula-
tion was shown to induce tetravalent immune response 
in 79.0% of subjects after only a single dose.7,10 The 
vaccine is being tested for its safety and immunoge-
nicity profile in phase II Clinical Trial in several sites 
around the world.
CONCLUSION
As mentioned above, several candidate vaccines are 
undergoing clinical trials. Most of them elicit good 
profiles of immunogenicity and reactogenicity when 
administered as a single vaccine, but none have achieved 
a good percentage of protection against dengue infections 
when used as a tetravalent vaccine. The reasons for this 
low efficacy are the possible viral interference among 
virus strains combined in the vaccines, the uncertainty 
about the levels of protective titers of neutralizing anti-
bodies, the possible lack of protection against strains 
different from those contained in the vaccines, and the 
evidence for the need of nonstructural proteins to elicit 
an adequate immune response. All candidate vaccines 
will have to deal with these questions before they are 
approved for human use. Finally, the vaccine candi-
date in the most advanced stage of development has 
just completed a phase III clinical trial and has induced 
an efficacy of a little less than 60.0%, and this efficacy 
has been achieved only after three doses of the vaccine. 
Even though this efficacy would result in a considerable 
reduction in the number of dengue cases, the questions 
are concerned to whom is going to use this vaccine and 
if there will be vaccines available for the whole world, in 
particular for developing countries, where dengue repre-
sents an important public health problem.
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